Europe Bladder Cancer Diagnostics Market, By Test Type (Cystoscopy, Urine Lab Test, Biopsy, Imaging Test, and Others), Stages (Stage I, Stage II, Stage III, and Stage IV), Cancer Type (Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, and Other Cancer Types), End User (Hospital, Diagnostic Imaging Centers, Cancer Research Institutes, Independent Diagnostic Laboratories, and Associated Labs), Distribution Channel (Direct Tender and Retail Sales) - Industry Trends and Forecast to 2030.
Europe Bladder Cancer Diagnostics Market Analysis and Size
Europe bladder cancer diagnostics market is fragmented in nature, as it consists of many Europe players such as F. Hoffmann-La Roche Ltd, Merck KGaA, Thermo Fisher Scientific Inc., Koninklijke Philips N.V., and Bio-Rad Laboratories, Inc. among others. The presence of these companies produces competitive prices for bladder cancer diagnostics across the region. Due to the presence of these players at regional and international levels, suppliers and manufacturers offer products with different specifications and characteristics in all budgets. The rising prevalence of bladder cancer is driving the market growth. Additionally, the rising awareness of the early detection of bladder cancer is expected to drive market growth.
Data Bridge Market Research analyzes that the Europe bladder cancer diagnostics market is expected to reach the value of USD 1,176.54 million by 2030, at a CAGR of 8.0% during the forecast period. This market report also covers pricing analysis and technological advancements in depth.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
Test Type (Cystoscopy, Urine Lab Test, Biopsy, Imaging Test, and Others), Stages (Stage I, Stage II, Stage III, and Stage IV), Cancer Type (Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, and Other Cancer Types), End User (Hospital, Diagnostic Imaging Centers, Cancer Research Institutes, Independent Diagnostic Laboratories, and Associated Labs), Distribution Channel (Direct Tender and Retail Sales)
|
|
Countries Covered
|
Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Rest of Europe
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd, Merck KGaA, Thermo Fisher Scientific Inc., Koninklijke Philips N.V., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., FUJIFILM Corporation, CANON MEDICAL SYSTEMS CORPORATION, Siemens Healthcare GmbH, BD, Illumina, Inc. Neusoft Corporation, Abbott, General Electric Company, Hologic Inc., QIAGEN, Cepheid, Ambu A/S, Time Medical Holding, and MinFound Medical Systems Co., among others
|
Market Definition
Bladder cancer begins when healthy cells in the bladder lining—most commonly urothelial cells—change and grow out of control, forming a mass called a tumor. Urothelial cells also line the renal pelvis and ureters, and urethra. Cancer that develops in the renal pelvis and ureters is also considered a type of urothelial cancer and is often called upper tract urothelial cancer. In most cases, it is treated in much the same way as bladder cancer which is described in this guide. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread. Benign bladder tumors are very rare.
Europe Bladder Cancer Diagnostics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
DRIVERS
Rising Incidence of Bladder Cancer Globally
Most gene mutations related to bladder cancer develop during a person's life rather than having been inherited before birth. Some of these acquired gene mutations result from exposure to cancer-causing chemicals or radiation. For instance, chemicals in tobacco smoke can be absorbed into the blood, filtered by the kidneys, and end up in urine, where they can affect bladder cells. Other chemicals may reach the bladder the same way. However, sometimes, gene changes may just be random events that sometimes happen inside a cell without having an outside cause.
Bladder cancer occurs mainly in older people. About 9 out of 10 people with this cancer are over the age of 55. The average age of people when they are diagnosed is 73. The rising cases of bladder cancer among the population are enhancing the use of bladder cancer diagnostic products and hence driving the growth of the bladder cancer diagnostics market.
Rising Awareness for the Early Diagnosis of Bladder Cancer
Bladder cancer awareness month is nationally recognized in the U.S. during the month of May. It aims at bringing together the bladder tumor community to help raise awareness and shine a light on a patient population that is often overlooked. Although bladder cancer is not as common as breast or lung cancer, the need for new and innovative ways to treat bladder tumor patients has never been more critical. Research suggests that more than 720,000 patients in the U.S. are struggling with bladder cancer.
As the current Europe health crisis continues to shift with the impact of COVID-19, the importance of understanding the impacts of patient care, education, and cancer research is becoming more apparent than ever. Looking toward the future, there is still much more groundwork to be done in discovering new and effective drugs for bladder tumor patients, as well as a dire need for continuous education on a multitude of challenges we face when treating bladder cancer.
Bladder cancer awareness month is a movement that is wholly dedicated to these efforts, and even in the midst of a pandemic, the need to help this patient population is still a top priority. Hence, the rising awareness of the early diagnosis of bladder cancer is driving the market's growth.
OPPORTUNITY
Increase in Diagnostic Procedures for Bladder Cancer
Bladder cancer is among the top ten most common cancers globally, causes considerable morbidity and mortality, and is, therefore, a substantial burden for healthcare systems. Several techniques used to diagnose bladder cancer include ultrasound, Computerized Tomography (CT) scans, Magnetic Resonance Imaging (MRI), and, sometimes, Positron Emission Tomography (PET) scans.
Treatment for bladder cancer with a slow growth rate may involve monitoring. Chemotherapy for malignant is occasionally combined with radiation therapy and stem cell transplant. People prefer the treatment and getting diagnosed more. Also, the increasing cancer rates have been a boosting factor for the increasing diagnostic product approval.
RESTRAINT / CHALLENGE
Side Effects of Bladder Cancer Treatment Drugs & Therapies
Chemotherapy (chemo) uses anti-cancer drugs that are usually given into a vein (IV) or taken by mouth. These drugs enter the bloodstream and reach almost all areas of the body. However, many chemo drugs aren't able to enter the bladder and reach tumor cells. Bacillus Calmette-Guerin (BCG) is the most common intravesical immunotherapy for treating early-stage bladder cancer. BCG is a germ that's related to the one that causes Tuberculosis (TB), but it doesn't usually cause serious diseases. When BCG is put into the bladder as a liquid through a catheter, it helps "turn on" the immune system cells there, which then attack the bladder cancer cells.
Chemo drugs can cause side effects. These depend on the type and dose of drugs and how long treatment lasts. Common side effects can include hair loss, mouth sores, loss of appetite, nausea & vomiting, diarrhea, increased chance of infections (from having too few white blood cells), easy bruising or bleeding (from having too few blood platelets), fatigue (from having too few red blood cells, changes in metabolism or other factors). Some chemo drugs can also cause other, less common side effects. For instance, cisplatin and carboplatin can also cause kidney damage and hearing loss. Sometimes, the doses of the drugs may need to be reduced, or treatment may need to be delayed or stopped to prevent the effects from getting worse. Hence, the side effects of bladder cancer treatment drugs & therapies may restrain the growth of the Europe bladder cancer diagnostics market.
Post-COVID-19 Impact on the Europe Bladder Cancer Diagnostics Market
COVID-19 created a negative impact on the Europe bladder cancer diagnostics market. The lockdown restriction led to the emergence of various challenges, such as decreased hospital visits and delays in treatment procedures.
The COVID-19 pandemic has impacted the market to an extent in a negative manner. However, increasing government support and advancements in imaging techniques are expected to provide lucrative opportunities for market growth. Moreover, increasing partnerships, acquisitions, and collaboration among market players are expected to further fuel market growth. Also, the growth has been high since the market opened after COVID-19, and it is expected that there will be considerable growth in the sector. The market players are conducting multiple activities to improve imaging techniques for the early detection of bladder cancer. With this, the companies will bring advancement and innovation to the market.
Recent Developments
- In May 2020, F. Hoffmann-La Roche Ltd acquired Stratos Genomics officially. With this acquisition, the company will also deal with the development of DNA-based sequencing for diagnostics use. This has enhanced the healthcare diagnosis segment of the company, thus leading to more revenue generation for the company.
- In January 2023, Thermo Fisher Scientific Inc. announced that it had completed the agreement to acquire The Binding Site Group, a Europe leader in specialty diagnostics. The acquisition will help in the development of the specialty diagnostics segment.
Europe Bladder Cancer Diagnostics Market Scope
Europe bladder cancer diagnostics market is segmented into five notable segments based test type, stages, cancer type, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Test Type
- Cystoscopy
- Urine Lab Test
- Biopsy
- Imaging Test
- Others
Based on test type, the market is segmented into cystoscopy, urine lab test, biopsy, imaging test, and others.
Stages
- Stage I
- Stage II
- Stage III
- Stage IV
Based on stages, the market is segmented into stage I, stage II, stage III, and stage IV.
Cancer Type
- Transitional Cell Bladder Cancer
- Squamous Cell Bladder Cancer
- Other Cancer Types
Based on cancer type, the market is segmented into transitional cell bladder cancer, squamous cell bladder cancer, and other cancer types.
End User
- Hospital
- Diagnostic Imaging Centers
- Cancer Research Institutes
- Independent Dignostic Laboratories
- Associated Labs
Based on end user, the market is segmented into hospital, diagnostic imaging centers, cancer research institutes, independent diagnostic laboratories, and associated labs.
Distribution Channel
- Direct Tender
- Retail Sales
Based on distribution channel, the market is segmented into direct tender and retail sales.
Europe Bladder Cancer Diagnostics Market Regional Analysis/Insights
The Europe bladder cancer diagnostics market is analyzed, and market size insights and trends are provided by country, test type, stages, cancer type, end user, and distribution channel as referenced above.
Countries covered in this market report are Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Rest of Europe.
Germany is expected to dominate the market with the largest market share. This share is attributable to the presence of key market players such as F. Hoffmann-La Roche Ltd, Merck KGaA, Thermo Fisher Scientific Inc., Koninklijke Philips N.V., and Bio-Rad Laboratories, Inc. among others. The rising prevalence of bladder cancer and improved imaging techniques are anticipated to fuel the market growth during the forecast period in this region.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe Bladder Cancer Diagnostics Market Share Analysis
Europe bladder cancer diagnostics market competitive landscape provides details of the competitor. Details included are company overview, company financials, revenue generated, market potential, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major market players operating in the Europe bladder cancer diagnostics market are F. Hoffmann-La Roche Ltd, Merck KGaA, Thermo Fisher Scientific Inc., Koninklijke Philips N.V., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., FUJIFILM Corporation, CANON MEDICAL SYSTEMS CORPORATION, Siemens Healthcare GmbH, BD, Illumina, Inc. Neusoft Corporation, Abbott, General Electric Company, Hologic Inc., QIAGEN, Cepheid, Ambu A/S, Time Medical Holding, and MinFound Medical Systems Co., among others.
SKU-